You are here: Industry Insights > UMCG

News List

Phase 2 Trials from Akston COVID-19 Vaccine Candidate americanpharmaceuticalreview
August 09, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate.
Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine americanpharmaceuticalreview
August 06, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate.
Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine americanpharmaceuticalreview
April 14, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first participants have been dosed in an open-label trial of AKS-452, its COVID-19 vaccine candidate.